Anaptysbio (ANAB) Net Income towards Common Stockholders (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$52.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 34.47% year-over-year to -$52.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.2 million (up 76.23% YoY) and the FY2025 annual result came in at -$12.6 million, up 88.99% from the prior year.
• Net Income towards Common Stockholders slipped to -$52.9 million in Q1 2026, from $50.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $50.2 million in Q4 2025 to a low of -$62.6 million in Q1 2023.
• A 5-year average of -$31.2 million and a median of -$39.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 94.94% — and 2025, when it soared 476.2%.
• Tracing ANAB's Net Income towards Common Stockholders over 5 years: stood at -$22.7 million in 2022, then sank by 85.61% to -$42.2 million in 2023, then surged by 120.67% to $8.7 million in 2024, then soared by 476.2% to $50.2 million in 2025, then slumped by 205.29% to -$52.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$52.9 million (Q1 2026), $50.2 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.